47 completed, 16 recruiting, 13 unknown, 11 active not recruiting. 103 Phase 2, 19 Phase 1, 3 Phase 3.
Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma DT-7012, Doxorubicin - Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS) | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 80 | 2027-02-01 | 2026-09-15 |
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Biopsy Procedure, Biospecimen Collection - Metastatic Myxoid Liposarcoma, Metastatic Synovial Sarcoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 42 | 2026-11-23 | 2026-09-25 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 80 | 2026-10-02 | 2026-10-09 |
| Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma Abemaciclib, Biopsy Procedure, Biospecimen Collection - Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2026-03-18 | 2026-10-21 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| A Study of Pembrolizumab in People With Ultra-Rare Sarcomas Pembrolizumab - Sarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 32 | 2025-12-04 | 2026-07-28 |
| Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors SA53-OS (phase 1), SA53-OS (phase 2) - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Lamassu Bio Inc | 55 | 2025-06-16 | 2026-11-09 |
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas STC-15 in combination with toripalimab, STC-15 monotherapy - Solid Tumor, Sarcoma | Phase 1 / Phase 2 | Recruiting | STORM Therapeutics LTD | 107 | 2025-05-05 | 2026-10-22 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma Mirdametinib, Palbociclib - Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2025-02-19 | 2026-09-16 |
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant - Cancer | Phase 2 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-01 | 2025-12-01 | |
| First-line Treatment of Advanced/unresectable DDLPS Liposomal Doxorubicin (Doxil), Apatinib, Camrelizumab - Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Not yet recruiting | Fudan University | 49 | 2024-12-01 | 2024-11-19 |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors Silmitasertib, Irinotecan, Temozolomide - Neuroblastoma, Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 104 | 2024-10-30 | 2026-11-12 |
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) Pemigatinib, Retifanlimab - Dedifferentiated Liposarcoma | Phase 2 | Recruiting | Lund University Hospital | 33 | 2024-06-20 | 2026-08-27 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas SPH4336 - Liposarcoma, Dedifferentiated | Phase 2 | Terminated | Shanghai Pharma Biotherapeutics USA Inc. | 14 | 2023-08-31 | 2025-06-13 |
| Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma Palbociclib, Cemiplimab, Magnetic Resonance Imaging - Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 77 | 2023-06-07 | 2026-10-20 |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Etrumadenant, Zimberelimab - Dedifferentiated Liposarcoma, Soft Tissue Sarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2023-05-23 | 2026-10-22 |
Showing 20 of 103. Sign in to see all of them.
Sarcoma (65) · Leiomyosarcoma (48) · Histiocytoma, Malignant Fibrous (33) · Sarcoma, Synovial (33) · Fibrosarcoma (27) · Hemangiosarcoma (26) · Neurofibrosarcoma (24) · Liposarcoma, Myxoid (21) · Rhabdomyosarcoma (21) · Dermatofibrosarcoma (14) · Osteosarcoma (13) · Sarcoma, Alveolar Soft Part (13) · Hemangiopericytoma, Malignant (11) · Malignant mesenchymal tumor (10)
Neoplasms by Histologic Type (103) · Neoplasms, Adipose Tissue (102) · Neoplasms, Connective and Soft Tissue (102) · Neoplasms (98) · Neoplasms, Connective Tissue (55) · Neoplasms, Muscle Tissue (51) · Neoplasms, Fibrous Tissue (42) · Sarcoma (38) · Histiocytoma (33) · Neoplasms, Nerve Tissue (30) · Neoplasms, Vascular Tissue (26) · Nervous System Diseases (24) · Nervous System Neoplasms (24) · Neurofibroma (24) · Neuromuscular Diseases (24)
Doxorubicin (11) · Trabectedin (8) · Radiotherapy (6) · pazopanib (6) · Biopsy (5) · Cyclophosphamide (5) · Docetaxel (4) · Gemcitabine (4) · Ifosfamide (4) · palbociclib (4) · pembrolizumab (4) · Imatinib Mesylate (3) · Magnetic Resonance Spectroscopy (3) · Radiation (3) · Radiation Dose Hypofractionation (3)
National Cancer Institute (NCI) (13) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Memorial Sloan Kettering Cancer Center (7) · Dana-Farber Cancer Institute (3) · Maria Sklodowska-Curie National Research Institute of Oncology (3) · Alliance for Clinical Trials in Oncology (2) · Brown University (2) · Fred Hutchinson Cancer Center (2) · Fudan University (2) · Grupo Espanol de Investigacion en Sarcomas (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · M.D. Anderson Cancer Center (2) · Oslo University Hospital (2) · Pfizer (2)
United States (66) · France (14) · Canada (11) · United Kingdom (11) · Spain (9) · Belgium (8) · China (7) · Germany (7) · Italy (7) · Netherlands (7) · Norway (5) · Denmark (4) · Israel (3) · Poland (3) · Sweden (3)
George D. Demetri, MD (3) · Benjamin Izar, MD (2) · Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · Margaret von Mehren, MD (2) · Mark Dickson, MD (2) · Robert Maki, MD, PhD (2) · Sandra D'Angelo, MD (2) · Seth Pollack (2) · Aaron R Weiss (1) · Alberto Chiappori, M.D. (1) · Alexander Wei, MD (1) · Annabel B.M. Foot (1)
PMID 31401903, PMID 32827353, PMID 19451433, PMID 10097144, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 19088049, PMID 19451429, PMID 20338746, PMID 20471824, PMID 20932656, PMID 21642514, PMID 22067397, PMID 23382028, PMID 23569312, PMID 24215845, PMID 26041763, PMID 27124835, PMID 27502708, PMID 29370992, PMID 30249211, PMID 30410720, PMID 31013172, PMID 31143880, PMID 32002290, PMID 32077895, PMID 32269142, PMID 32641862, PMID 32701199, PMID 32702309, PMID 33180100, PMID 34260265, PMID 34515544, PMID 35115306, PMID 35394800, PMID 35507536, PMID 36129471, PMID 36987836, PMID 37523624, PMID 38236580, PMID 39034053
P30CA015704 (3), P30CA006516 (2), P30CA008748 (2), U10CA098543 (2), U10CA180821 (2), UM1CA186709 (2), 2004 (1), 2015 (1), N01CM62203 (1), N01CM62206 (1), P30CA012197 (1), P30CA016672 (1), P30CA060553 (1), R21CA117128 (1), U01CA069856 (1)